Expert Ratings For Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Travere Therapeutics (NASDAQ:TVTX) over the past quarter, with a range of price targets from $12.00 to $19.00. The average price target has increased by 12.07% to $16.25. Key analysts have raised their ratings and price targets, reflecting evolving market dynamics and company performance.
August 02, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided mixed ratings for Travere Therapeutics (NASDAQ:TVTX) over the past quarter, with a range of price targets from $12.00 to $19.00. The average price target has increased by 12.07% to $16.25. Key analysts have raised their ratings and price targets, reflecting evolving market dynamics and company performance.
The increase in the average price target by 12.07% and the raised ratings from key analysts suggest a positive outlook for Travere Therapeutics. This is likely to have a short-term positive impact on the stock price as investors react to the improved sentiment and higher price targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100